Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11261254 Antibodies

Patent 11261254 was granted and assigned to Genmab A/S on March, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Sieto Bosgra0

Louise Koopman0

Patrick Engelberts0

Rik Rademaker0

David Satijn0

Dennis Verzijl0

Edward N. Van Den Brink0

Esther C. W. Breij0

...

Date of Patent

March 1, 2022

Patent Application Number

17494545

Date Filed

October 5, 2021

Patent Citations

US Patent 10590206 Inert format

US Patent 10906991 Bispecific antibodies and methods for production thereof

0

US Patent 10597464 Heterodimeric antibody Fc-containing proteins and methods for production thereof

US Patent 10150813 Anti-B7-H4 antibodies and immunoconjugates

US Patent 10344050 Production of heterodimeric proteins

0

US Patent 10407501 Humanized or chimeric CD3 antibodies

0

US Patent 10465006 Humanized or chimeric CD3 antibodies

US Patent 10544220 Bispecific antibodies against CD3 and CD20

Patent Primary Examiner

Meera Natarajan

Patent abstract

The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11261254 Antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool